These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

595 related items for PubMed ID: 23333143

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, Brooks JK, Bhatt DL, Michelson AD.
    J Am Coll Cardiol; 2012 Apr 03; 59(14):1304-11. PubMed ID: 22464259
    [Abstract] [Full Text] [Related]

  • 3. Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.
    Funck-Brentano C, Szymezak J, Steichen O, Ducint D, Molimard M, Remones V, Azizi M, Gaussem P.
    Arch Cardiovasc Dis; 2013 Dec 03; 106(12):661-71. PubMed ID: 24246616
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel.
    Fernando H, Bassler N, Habersberger J, Sheffield LJ, Sharma R, Dart AM, Peter KH, Shaw JA.
    J Thromb Haemost; 2011 Aug 03; 9(8):1582-9. PubMed ID: 21696537
    [Abstract] [Full Text] [Related]

  • 6. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways.
    Braun OÖ, Angiolillo DJ, Ferreiro JL, Jakubowski JA, Winters KJ, Effron MB, Duvvuru S, Costigan TM, Sundseth S, Walker JR, Saucedo JF, Kleiman NS, Varenhorst C.
    Thromb Haemost; 2013 Dec 03; 110(6):1223-31. PubMed ID: 24009042
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.
    Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, Isserman S, Rogers WJ, Ruff CT, Contant C, Pencina MJ, Scirica BM, Longtine JA, Michelson AD, Sabatine MS.
    JAMA; 2011 Nov 23; 306(20):2221-8. PubMed ID: 22088980
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
    Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, Gurbel PA.
    Circ Cardiovasc Genet; 2010 Dec 23; 3(6):556-66. PubMed ID: 21079055
    [Abstract] [Full Text] [Related]

  • 14. Genetic polymorphisms and the impact of a higher clopidogrel dose regimen on active metabolite exposure and antiplatelet response in healthy subjects.
    Simon T, Bhatt DL, Bergougnan L, Farenc C, Pearson K, Perrin L, Vicaut E, Lacreta F, Hurbin F, Dubar M.
    Clin Pharmacol Ther; 2011 Aug 23; 90(2):287-95. PubMed ID: 21716274
    [Abstract] [Full Text] [Related]

  • 15. Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
    Wang XQ, Shen CL, Wang BN, Huang XH, Hu ZL, Li J.
    Gene; 2015 Mar 10; 558(2):200-7. PubMed ID: 25542807
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.
    Danese E, Fava C, Beltrame F, Tavella D, Calabria S, Benati M, Gelati M, Gottardo R, Tagliaro F, Guidi GC, Cattaneo M, Minuz P.
    J Thromb Haemost; 2016 Feb 10; 14(2):282-93. PubMed ID: 26576037
    [Abstract] [Full Text] [Related]

  • 18. Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade.
    Bonello L, Camoin-Jau L, Mancini J, Bessereau J, Grosdidier C, Alessi MC, Ostorero M, Dignat-George F, Paganelli F.
    Thromb Res; 2012 Jul 10; 130(1):70-4. PubMed ID: 22285300
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
    Harvey A, Modak A, Déry U, Roy M, Rinfret S, Bertrand OF, Larose É, Rodés-Cabau J, Barbeau G, Gleeton O, Nguyen CM, Proulx G, Noël B, Roy L, Paradis JM, De Larochellière R, Déry JP.
    J Breath Res; 2016 Jan 27; 10(1):017104. PubMed ID: 26815196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.